{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:38:44Z","timestamp":1781656724869,"version":"3.54.5"},"reference-count":21,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020604","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020604","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2234776","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T07:23:20Z","timestamp":1689060200000},"page":"915-923","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Health care resource utilization in 3L\u2009+\u2009patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib"],"prefix":"10.1080","volume":"26","author":[{"given":"Jorge E.","family":"Cortes","sequence":"first","affiliation":[{"name":"Georgia Cancer Center at Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Rea","sequence":"additional","affiliation":[{"name":"Hopital Saint-Louis, APHP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4207-7554","authenticated-orcid":false,"given":"Diana","family":"Tran","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Wang","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejal","family":"Jadhav","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Yocolly","sequence":"additional","affiliation":[{"name":"Novartis Services Inc, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, The University of Texas, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"American Cancer Society. Key statistics for chronic myeloid leukemia. Atlanta (GA): American Cancer Society; [cited 2022 Aug 5]. Available from: https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00194"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25792"},{"key":"e_1_3_5_5_1","unstructured":"Mayo Clinic. Chronic myelogenous leukemia. USA: Mayo Clinic; [cited 2022 Aug 5]. Available from: https:\/\/www.mayoclinic.org\/diseases-conditions\/chronic-myelogenous-leukemia\/symptoms-causes\/syc-20352417"},{"key":"e_1_3_5_6_1","volume-title":"Cancer facts & figures 2019","author":"American Cancer Society","year":"2019","unstructured":"American Cancer Society. Cancer facts & figures 2019. Atlanta (GA): American Cancer Society; 2019."},{"key":"e_1_3_5_7_1","unstructured":"National Cancer Institute. Cancer stat facts: leukemia\u2014chronic myeloid leukemia (CML). Bethesda (MD): SEER; [cited 2022 Aug 5]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"},{"key":"e_1_3_5_8_1","unstructured":"National Health Service (NHS). Chronic myeloid leukaemia. UK: National Health Service; [cited 2023 Aug 5]. Available from: https:\/\/www.nhs.uk\/conditions\/chronic-myeloid-leukaemia\/"},{"key":"e_1_3_5_9_1","unstructured":"U.S. Food & Drug Administration. FDA approves asciminib for Philadelphia chromosome-positive chronic myeloid leukemia. USA: Food & Drug Administration; [cited 2022 Aug 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia"},{"key":"e_1_3_5_10_1","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY. Japan: Pharmaceuticals and Medical Devices Agency; [cited 2022 Aug 5]. Available from: https:\/\/www.pmda.go.jp\/files\/000246734.pdf"},{"key":"e_1_3_5_11_1","unstructured":"European Medicines Agency. Scemblix. The Netherlands: European Medicines Agency; [cited 2022 Aug 5]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/scemblix"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7502"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719826444"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7004"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1120189"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.04.321"},{"key":"e_1_3_5_19_1","unstructured":"ClinicalTrials.gov. Study of efficacy of CML-CP patients treated with ABL001 versus bosutinib previously treated with 2 or more TKIs. USA: National Institutes of Health; [cited 2022 Aug 5]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03106779"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)01781-X"},{"key":"e_1_3_5_21_1","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2022","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2022."},{"key":"e_1_3_5_22_1","unstructured":"National Institute for Health and Care Excellence. Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]: committee papers. UK: National Institute for Health and Care Excellence; [cited 2023 Jul 3]."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2234776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:04:52Z","timestamp":1701943492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2234776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2234776"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2234776","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}